Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CDX-1140 + PGG beta-glucan |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CDX-1140 | CDX 1140|CDX1140 | CD40 Antibody 14 | CDX-1140 is an antibody that binds CD40 and activates signaling, potentially resulting in enhanced anti-tumor immune response (Blood, 128(22), 1848, PMID: 30382327). | |
PGG beta-glucan | Imprime PGG|Odetiglucan | Imprime PGG (PGG beta-glucan) binds to and promotes cytotoxicity of neutrophils bound to tumor cells via complement receptor 3 (CR3) (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05484011 | Phase I | CDX-1140 + PGG beta-glucan | A Maintenance Therapy Study of Odetiglucan With a CD40 Agonist (CDX-1140) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | Terminated | USA | 0 |